Abstract: Liquid formulations of bone morphogenetic proteins are provided for prolonged use at elevated temperatures. More specifically, the invention relates to liquid formulations comprising rhGDF-5, trehalose, and one or more biocompatible excipients that provide stability to the protein for at least 30 days at temperatures up to body temperature.
Type:
Grant
Filed:
June 24, 2008
Date of Patent:
March 16, 2010
Assignee:
Johnson & Johnson Regenerative Therapeutics, LLC
Inventors:
Venkata Garigapati, Dongling Su, Julius Lopez
Abstract: We isolated and characterized a new surface mutant of the hepatitis B virus surface antigen (HBsAg). The mutant was isolated from a symptomatic patient with Down's syndrome who was found to be persistently positive for both for HBsAg and anti-HBs Antibody (Ab) with an equally long-lasting anti-HB core (c) IgM Ab.
Abstract: The present invention relates to new CRP immunoassay compositions. The compositions include a low affinity anti-human CRP monoclonal antibody, and an antiidiotypic antibody raised against it. The invention further provides a method for obtaining antiidiotypic monoclonal antibody populations directed to an antibody that is specific for a high concentration, high molecular weight target antigen.
Abstract: The present invention relates to compositions comprising novel reduced cortisol conjugates, methods for their preparation and use in immunoassays for cortisol.
In another aspect, it relates to conjugates of reduced cortisol as immunogens or haptens for eliciting anti-cortisol or anti-reduced cortisol antibodies.
Type:
Grant
Filed:
September 30, 1999
Date of Patent:
May 7, 2002
Assignee:
Ortho-Clinical Diagnostics, Inc.
Inventors:
Harold C. Warren, Brian A. Snyder, Lisa D. Sprague, Shirley Y. Lynn, Paul B. Contestable, Holly L. Groth
Abstract: This invention relates to peptides and their preparation. The peptides each have a sequence that corresponds to the immunodominant region of the HIV-1 group O gp41 envelope protein. The sequence is characterized in that it does not correspond to any known naturally occurring group O sequence or variant. Furthermore, the peptide binds anti-HIV-1 group O antibodies. There are several uses for the peptides, including the detection of antibodies produced in response to HIV-1 group O infection. The peptides may also be incorporated in mosaics and expressed recombinantly.
Abstract: The present invention relates to an immunoassay for antibodies against an infectious agent. The present invention also relates to the use of the immunoassay and a kit for performing the immunoassay of the present invention. The immunoassay for antibodies against an infectious agent relates to a method comprising: i. incubating a sample suspected of containing said antibodies with immobilized antigen of the infectious agent and free labeled antigen of the infectious agent; ii. separating immobilized components from non-immobilized components; iii. incubating the immobilized components with further free labeled antigen of the infectious agent and removing non-immobilized components; and iv. determining the amount of labeled antigen immobilized, wherein the amount of label is indicative of the amount of said antibodies present in the sample.